TerminatedNot Applicable

Inflammatory Consequences of Crystalloids in Severely Burned Patients

Stopped: Lack of funds and participants

Canada14 participantsStarted 2021-10-17

Plain-language summary

This is a pilot study, but the investigators will also observe key immunological events with potential significance. The global objective is to study the inflammatory profiles of PlasmaLyte and Ringer's Lactate used in the initial massive fluid resuscitation of severely burned patients. On the long term, the investigators will identify the crystalloid that prevents hyperactivation of macrophages and death of severely burned patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * admission to the CHUM * more than 20% of burned area * first blood withdrawal in the first 24 hours following burn Exclusion Criteria: * immunosuppression * chemotherapy 6 months before admission * radiotherapy 6 months before admission * autoimmune diseases * neoplasia * pregnancy * severe infections * cardiac dysfunctions * renal dysfunction * hepatic dysfunctions * Hepatitis C * HIV

What they're measuring

Change in monocyte phenotype from admission to day 10

Timeframe: Pre-infusion to day 10 post-infusion

Trial details

NCT IDNCT04893382

SponsorCentre hospitalier de l'Université de Montréal (CHUM)

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-19

View on ClinicalTrials.gov More Burns trials